BKB Growth Investments, LLC - 25 Nov 2025 Form 3 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
10%+ Owner
Signature
BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager
Issuer symbol
VRCA
Transactions as of
25 Nov 2025
Net transactions value
$0
Form type
3
Filing time
26 Jan 2026, 16:23:59 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BKB Growth Investments, LLC 10%+ Owner C/O TIGER LILY CAPITAL, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE BKB Growth Investments, LLC, By: Tiger Lily Capital, LLC, its manager By: /s/ Paul Manning, its manager 26 Jan 2026 0002101167
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VRCA Common Stock 3,348,372 25 Nov 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VRCA Series B Warrants (right to buy) 25 Nov 2025 Common Stock 224,719 $1.34 Direct F1, F2
holding VRCA Series C Warrants (right to buy) 25 Nov 2025 Common Stock 687,690 $6.32 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 The Reporting Person will not be entitled to exercise any portion of a Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
F3 The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 19.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.